These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 8426839)
21. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. Mukherjee P; Sotnikov AV; Mangian HJ; Zhou JR; Visek WJ; Clinton SK J Natl Cancer Inst; 1999 Mar; 91(6):512-23. PubMed ID: 10088621 [TBL] [Abstract][Full Text] [Related]
22. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Landström M; Damber JE; Bergh A Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874 [TBL] [Abstract][Full Text] [Related]
23. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Wikström P; Lindahl C; Bergh A Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804 [TBL] [Abstract][Full Text] [Related]
24. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W Prostate; 1990; 16(4):313-23. PubMed ID: 2371176 [TBL] [Abstract][Full Text] [Related]
25. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Joon DL; Hasegawa M; Sikes C; Khoo VS; Terry NH; Zagars GK; Meistrich ML; Pollack A Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):1071-7. PubMed ID: 9276374 [TBL] [Abstract][Full Text] [Related]
26. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines. Fuerst J; Fiebiger E; Jungwirth A; Mack D; Talwar PG; Frick J; Rovan E Prostate; 1997 Jul; 32(2):77-84. PubMed ID: 9215394 [TBL] [Abstract][Full Text] [Related]
27. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Häggström S; Wikström P; Bergh A; Damber JE Prostate; 1998 Jul; 36(2):71-9. PubMed ID: 9655258 [TBL] [Abstract][Full Text] [Related]
28. Quiescence in R3327-G rat prostate tumors after androgen ablation. Pollack A; Joon DL; Wu CS; Sikes C; Hasegawa M; Terry NH; White RA; Zagars GK; Meistrich ML Cancer Res; 1997 Jun; 57(12):2493-500. PubMed ID: 9192831 [TBL] [Abstract][Full Text] [Related]
29. Dose/response study of the effects of oestrogens on tumour growth and morphology in the Dunning R3327 prostatic adenocarcinoma. Landström M; Damber JE; Bergh A; Tomic R J Cancer Res Clin Oncol; 1992; 118(1):30-4. PubMed ID: 1729258 [TBL] [Abstract][Full Text] [Related]
30. Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma. Schiller CD; Schneider MR; Hartmann H; Graf AH; Klocker H; Bartsch G Urol Res; 1991; 19(1):7-13. PubMed ID: 1827559 [TBL] [Abstract][Full Text] [Related]
31. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Friedrich B; Grönberg H; Landström M; Gullberg M; Bergh A Prostate; 1995 Aug; 27(2):102-9. PubMed ID: 7638082 [TBL] [Abstract][Full Text] [Related]
32. Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation. Kager M; Spruss T; Schneider MR; von Angerer E J Cancer Res Clin Oncol; 1992; 118(5):334-8. PubMed ID: 1583064 [TBL] [Abstract][Full Text] [Related]
33. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation. Pollack A; Block NL; Stover BJ; Irvin GL Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360 [TBL] [Abstract][Full Text] [Related]
34. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Zaccheo T; Giudici D; di Salle E Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146 [TBL] [Abstract][Full Text] [Related]
35. Fractionated radiotherapy of rat prostatic adenocarcinoma (Dunning R3327-PAP) in nonanesthetized animals. Granfors T; Bergh A; Löfroth PO; Widmark A Prostate; 1999 Apr; 39(1):16-22. PubMed ID: 10221261 [TBL] [Abstract][Full Text] [Related]
36. Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. Landström M; Funa K Int J Cancer; 1997 May; 71(3):451-5. PubMed ID: 9139883 [TBL] [Abstract][Full Text] [Related]
37. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Halin S; Hammarsten P; Wikström P; Bergh A Prostate; 2007 Mar; 67(4):370-7. PubMed ID: 17192959 [TBL] [Abstract][Full Text] [Related]
38. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma. Ip MM; Milholland RJ; Rosen F Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787 [TBL] [Abstract][Full Text] [Related]
39. Visualization and quantification of transplanted Dunning prostate tumors in rats using magnetic resonance imaging. Rudin M; Qureshi S; Tolcsvai L; Siegel RA Prostate; 1988; 12(4):333-41. PubMed ID: 3393495 [TBL] [Abstract][Full Text] [Related]
40. Alterations of physical and biochemical parameters of the R3327-CP rat prostate adenocarcinoma following hormonal manipulation of the host. Buttyan R; Tomashefsky P; Deitch AD; Olsson CA; Devere-White R J Urol; 1984 Jun; 131(6):1218-24. PubMed ID: 6726931 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]